Form 4: Vor Biopharma Reprices CDO Stock Options to $8.18

Vor Biopharma's Chief Development Officer, Qing Zuraw, had her stock options repriced to $8.18 per share following a reverse stock split and significant stock value decline.

Summary

• Qing Zuraw, Chief Development Officer of Vor Biopharma Inc. (VOR), had her employee stock options repriced.
• The repricing was effective December 5, 2025, under the Issuer's Amended and Restated 2021 Equity Incentive Plan and 2023 Inducement Plan.
• The original exercise price of the options was $47.6 per share, which reflected a 1-for-20 reverse stock split effected on September 18, 2025.
• The new exercise price for the 218,652 shares underlying the option is $8.18 per share, representing the fair market value on the effective date.
• The options will vest 1/4th on July 17, 2026, with the remainder vesting in substantially equal monthly installments over 3 years, subject to continued service.
• A 'Retention Period' is in effect, during which the repriced stock option will revert to its original exercise price if exercised. This period ends upon the earliest of 24 months from the effective date, a Change in Control, or 30 days prior to the option's original expiration date.
• The option's expiration date is July 16, 2035.

Sentiment

Score: 3

Explanation: The repricing of executive stock options, while intended to re-incentivize a key officer, is a direct consequence of a significant decline in the company's stock price. This reflects negatively on past performance and market perception, despite the forward-looking positive intent for executive retention.

Positives

• The repricing re-incentivizes Chief Development Officer Qing Zuraw by making her stock options 'in-the-money' again, potentially improving retention and motivation for a key executive.
• The action was approved by the Board of Directors under existing equity incentive plans, indicating adherence to established corporate governance frameworks.

Negatives

• The repricing from an adjusted original exercise price of $47.6 to $8.18 per share strongly implies a significant decline in the company's stock value, which is negative for existing shareholders.
• The 'Retention Period' clause, where the option reverts to the original exercise price if exercised during this period, adds complexity and uncertainty to the immediate benefit for the optionholder.

Risks

• The significant drop in stock price that necessitated the repricing indicates underlying business challenges or market perception issues for Vor Biopharma.
• The 'Retention Period' introduces a risk for the optionholder, as exercising during this period would negate the benefit of the repricing, potentially impacting the intended incentive.
• Potential for shareholder dissatisfaction due to the repricing, especially if the stock price does not recover significantly, as it effectively grants new options at a much lower strike price.

Future Outlook

The filing indicates a future vesting schedule for the repriced options, with 1/4th vesting on July 17, 2026, and the remainder vesting monthly over the subsequent three years, contingent on the reporting person's continued service.

Industry Context

Stock option repricing is a mechanism often employed by biotechnology companies, particularly after significant declines in stock price, to re-incentivize key executives whose original options have become 'underwater.' This aims to retain talent and re-align executive compensation with current market realities, which is a common practice in the volatile biotech sector.

Comparison to Industry Standards

• Repricing of underwater stock options is a common strategy in the biotech industry, similar to actions taken by companies like Editas Medicine (EDIT) or CRISPR Therapeutics (CRSP) during periods of significant stock price volatility, to retain critical scientific and development talent.
• The inclusion of a 'Retention Period' where the option reverts to its original exercise price if exercised during that time is a less common, but not unheard of, clause designed to mitigate immediate 'windfall' gains and ensure longer-term commitment, potentially seen in more conservative repricing structures.

Corporate Governance

Stakeholder Impact

• Shareholders: The repricing reflects a significant decline in stock value, which is negative for existing shareholders. While intended to retain talent, it could be viewed as dilutive or a reward for past underperformance if the stock does not recover.
• Employees (specifically the CDO): The Chief Development Officer benefits from renewed incentive as her options are now 'in-the-money,' potentially increasing motivation and retention.
• Creditors: No direct impact mentioned, but a significant stock price decline could indirectly affect the company's financial standing and creditworthiness.

Next Steps

• Continued vesting of the repriced stock options according to the specified schedule, subject to the Chief Development Officer's continued service.

Key Dates

Recommendation

The repricing of executive stock options, while beneficial for executive retention and motivation, typically follows a substantial decline in the company's stock price. This suggests underlying challenges or underperformance. Investors should hold to observe if the repricing successfully re-aligns executive incentives with future stock appreciation, but the past performance leading to this action warrants caution. A 'buy' would be premature given the implied past struggles, and a 'sell' might be an overreaction if the repricing helps stabilize the company and its leadership.

Keywords

Vor Biopharma, VOR, stock option repricing, executive compensation, Form 4, SEC filing, equity incentive plan, reverse stock split, Chief Development Officer